- Home
- NSTS vs IVVD Comparison
NSTS vs IVVD Comparison
Compare NSTS & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | IVVD |
|---|---|---|
| Founded | 1921 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 437.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NSTS | IVVD |
|---|---|---|
| Price | $12.20 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 2.3K | ★ 1.6M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | $256,000.00 | ★ $53,426,000.00 |
| Revenue This Year | N/A | $143.48 |
| Revenue Next Year | N/A | $25.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $10.73 | $0.46 |
| 52 Week High | $13.06 | $3.07 |
Technical Indicators
Market Signals| Indicator | NSTS | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 51.65 |
| Support Level | $11.91 | $1.41 |
| Resistance Level | $12.30 | $2.01 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 12.50 | 57.32 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.